Journal
MOLECULAR THERAPY
Volume 19, Issue 10, Pages 1826-1832Publisher
CELL PRESS
DOI: 10.1038/mt.2011.154
Keywords
-
Categories
Funding
- National Institutes of Health [HL-91883]
- Muscular Dystrophy Association
Ask authors/readers for more resources
Dystrophin deficiency leads to lethal dilated Duchenne cardiomyopathy. A promising therapy is to deliver a highly abbreviated microdystrophin gene to the heart using adeno-associated virus (AAV). Microdystrophin has been shown to mitigate dystrophin-deficient skeletal muscle disease. However, it is not clear whether microdystrophin is equally effective in treating Duchenne cardiomyopathy. To evaluate microdystrophin therapy in the heart, we injected 5 x 10(12) viral genome particles/ mouse of AAV-9 Delta R4-23/Delta C microdystrophin vector via tail vein to similar to 16-20-month-old (average 18.7-month-old) female mdx mice, a manifesting model of Duchenne cardiomyopathy. Cardiac transduction and heart function were examined at 2-8 months after gene transfer. We observed robust myocardial microdystrophin expression. Electrocardiography (ECG) and left ventricular catheter hemodynamic assays also revealed significant improvement. Furthermore, AAV-microdystrophin therapy prevented dobutamine-stress induced acute cardiac death. We demonstrate for the first time that AAV microdystrophin therapy significantly ameliorates functional deficiency in a phenotypic model of Duchenne cardiomyopathy. Our results support further exploration of microdystrophin therapy to treat Duchenne cardiomyopathy. Received 4 February 2011; accepted 24 June 2011; published online 2 August 2011. doi:10.1038/mt.2011.154
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available